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Abstract
Reduction of gametocyte transmission from humans to mosquitoes is a key component of malaria elimination. The
study by Gonçalves and colleagues provides valuable new data on how the addition of low-dose primaquine to
artemether-lumefantrine affects reduction of gametocytemia and transmission of gametocytes to mosquitoes in
asymptomatically Plasmodium falciparum-infected children without G6PD deficiency, and on the degree to which
low-dose primaquine affects hemoglobin levels in these children. The study sets the stage for future research
required for consideration of an artemisinin combination therapy (ACT)-primaquine regimen in mass drug
administration campaigns. Future studies will need to evaluate toxicity in adults and G6PD deficient persons, assess
gametocyte transmission from adults, evaluate different ACT drugs with primaquine, and assess the implications of
“rare” toxicities in large treatment populations, such as hemolysis requiring blood transfusion. The study highlights
both the promise and the potential risk of ACT-primaquine treatment in malaria elimination campaigns.
Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0581-y.
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Background
Primaquine + artemisinin combination therapy (ACT) for
malaria elimination
As countries consider campaigns to eliminate malaria,
the question of gametocyte transmission from the hu-
man to mosquito host takes center stage: without reduc-
tion of gametocyte transmission to low or zero levels, it
will be hard to achieve malaria elimination. Artemether-
lumefantrine (AL), the most common first-line artemisi-
nin combination therapy (ACT) for treatment of malaria
in Africa, reduces gametocytemia and gametocyte trans-
mission to mosquitoes, but does so less effectively than
primaquine. Current World Health Organization
(WHO) guidelines state that “in elimination areas which
have not yet adopted primaquine as a gametocytocide
for P. falciparum malaria, a single 0.25 mg base/kg
primaquine dose should be given to all patients with
parasitologically-confirmed P. falciparum malaria on the
first day of treatment in addition to an ACT, except for
pregnant women and infants < 1 year of age” [1]. Most
studies of children with symptomatic malaria treated
with ACT alone show that, regardless of the ACT used,
a small percentage of children continue to transmit
gametocytes to mosquitoes 7–14 days after treatment
[2–4]. However, similar studies in children with asymp-
tomatic parasitemia are lacking, and there is little data
on how the addition of primaquine to ACT might alter
gametocyte transmission in this population. A key issue
with the addition of primaquine to ACT is the risk of
hemolysis with primaquine, a risk that is substantially
increased in individuals with glucose-6-phosphate de-
hydrogenase (G6PD) deficiency, a condition common in
sub-Saharan Africa.
Gonçalves et al. address this gap through a well-
designed and carefully conducted study in which they
assessed the efficacy of AL, AL plus 0.25 mg/kg of
primaquine, or AL plus 0.40 mg/kg of primaquine on re-
duction of gametocytemia and gametocyte transmission
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in 360 children in Burkina Faso who were asymptomati-
cally infected with Plasmodium falciparum [5]. Screen-
ing for G6PD deficiency was done with BinaxNOW
rapid testing, and only children without G6PD deficiency
were enrolled in the study. The addition of primaquine
to AL significantly reduced the prevalence of gametocy-
temia. However, though prevalence of gametocytemia as
measured by Pfs25 quantitative nucleic acid sequence-
based amplification (QT-NASBA) was still 10–42 % in
the different study arms 14 days after treatment initi-
ation, only one child (in the AL alone arm) transmitted
gametocytes to mosquitoes in the 3 to 14 days after
treatment initiation. The study findings suggest that
gametocyte transmission to mosquitoes from children
with asymptomatic parasitemia is lower than in symptom-
atic children, and that AL or AL plus primaquine at either
dose all substantially reduce gametocyte transmission
from asymptomatically infected children to mosquitoes.
Two children had a hemoglobin decrease of > 4 g/dL, and
both were on primaquine treatment (one at 0.4 mg/kg,
one at 0.25 mg/kg). The study provides valuable new data
that enhances our understanding of the additive effects of
low-dose primaquine to AL on gametocytemia and on
transmission of gametocytes, but also highlights the need
for additional studies on the role of primaquine supple-
mentation to ACT in reducing malaria transmission.
Infectivity in asymptomatic vs. symptomatic infection,
and in children vs. adults
For example, further studies are needed to define who
should be treated with an ACT-primaquine combination
for malaria elimination: asymptomatic individuals in a
mass screen and treat or mass drug administration
(MDA) program, only symptomatic individuals who seek
treatment, or both symptomatic and asymptomatic indi-
viduals? In areas of unstable transmission, rates of
asymptomatic gametocytemia may remain high during
the low malaria transmission season, so the population
can easily transmit gametocytes to mosquitoes when the
mosquito population increases [6]. In these areas, MDA
to asymptomatic individuals in the off-peak season will
be critical. However, some areas with very low transmis-
sion, such as the Nandi Hills highland areas of Kenya
where we have conducted studies, appear to have little
to no asymptomatic parasitemia or gametocytemia dur-
ing low malaria transmission periods [7]. In these areas,
rapid treatment of symptomatic individuals with ACT-
primaquine combinations or possibly seasonal malaria
chemoprophylaxis may be more effective to reduce mal-
aria transmission or incidence than an MDA campaign
that treats few or no infected individuals.
In addition, most studies that have assessed gameto-
cyte transmission have assessed transmission from in-
fected children [2, 4, 8], but infected adults can also
transmit gametocytes. Studies of the effect on ACT-
primaquine combinations on reduction of gametocyte
transmission from adults are needed, because MDA
campaigns aiming for malaria elimination will target
children and adults. Also, as the authors point out, the
membrane feeding assays they and others have used
underestimate human to mosquito gametocyte transmis-
sion when compared to superior but impractical direct
mosquito feeding assays. Studies using membrane feed-
ing may therefore overestimate the efficacy of, for ex-
ample, AL alone in reducing gametocyte transmission.
Models that account for this underestimation may be re-
quired for accurate planning of MDA campaigns.
ACT: the complex effects and interactions of the partner
drug
The long half-life of piperaquine may make
dihydroartemisinin-piperaquine (DP) the ACT of choice
for MDA campaigns. Modeling studies also suggest that
in elimination campaigns primaquine is most effective
when partnered with a long-lasting prophylactic drug
like DP [9]. However, DP appears to be less effective
than AL in reducing gametocyte transmission to mos-
quitoes in children with uncomplicated malaria [4]. It is
possible that the addition of primaquine may therefore be
more important in MDA elimination campaigns using DP
than AL, because primaquine may be more important for
reduction of gametocyte transmission in individuals
treated with DP as opposed to AL. Hematologic toxicities
with piperaquine as compared to lumefantrine as the
ACT partner drug are not yet known. A recent study
showed that primaquine does decrease gametocyte trans-
mission when added to DP as treatment for uncompli-
cated malaria [10]. The investigators in the present study
are currently pursuing the logical next study, assessing the
effect of DP plus primaquine on gametocyte transmission
in asymptomatically infected children in the Gambia [11].
The results of this study will be important to assessments
of the feasibility and safety of MDA programs with DP-
primaquine combinations.
Population-level toxicity: primaquine-related hemolysis
with or without G6PD deficiency
Ultimately, however, the place of primaquine in addition
to ACT in MDA campaigns depends not only on its effi-
cacy in reducing gametocyte transmission but also on its
safety in MDA programs. The primary safety concern
with primaquine treatment is hemolysis and consequent
anemia. Primaquine was used safely in MDA programs
outside Africa for P. vivax elimination [12], but the
prevalence of G6PD deficiency and anemia in those
countries differs greatly from that in African countries.
In a study in Tanzania, Shekalaghe et al. found that
primaquine at 0.75 mg/kg combined with sulfadoxine-
John BMC Medicine  (2016) 14:65 Page 2 of 3
pyrimethamine (SP) and artesunate led to a significant
reduction in hemoglobin in children when compared to
SP plus artesunate alone [13]. Decreases in hemoglobin
were greatest in children with G6PD deficiency, but also
occurred in children without G6PD deficiency (as de-
fined by genetic testing). In the study by Gonçalves
et al., decreases in hemoglobin were greater with prima-
quine treatment, though the differences reach statistical
significance only for the 0.4 mg/kg primaquine arm [5].
A hemoglobin decrease of > 4 g/dL occurred in 1 of 75
children (1.3 %) and 1 of 73 children (1.4 %) in the
0.4 mg/kg and 0.25 mg/kg primaquine arms, respect-
ively. Hemoglobin levels recovered by the end of the
study (apparently without intervention), and no child re-
quired a blood transfusion.
However, the possibility that ~ 1 % of children in a low-
dose primaquine MDA program may have a > 4 g/dL de-
crease in hemoglobin raises significant concerns. In the
study by Gonçalves et al, only children with a hemoglobin
level ≥ 8/dL who were not G6PD deficient were eligible
for participation [5]. Risks of hemolysis in children with
G6PD deficiency will be substantially higher. Before MDA
campaigns with low-dose primaquine are considered, as-
sessment of safety in G6PD deficient African children is
imperative, because accurate testing for G6PD deficiency
in mass campaigns will likely not be feasible. Furthermore,
will MDA campaigns be able to screen for anemia and
exclude anemic children? How many of those anemic
children will be gametocytemic? How many serious
adverse events will occur if ~ 1 % of children have a
hemoglobin drop of > 4 g/dL? How many children will
have a decrease in hemoglobin that requires blood trans-
fusion? Even a very low 0.1 % incidence rate will result in
100 such events in a population of 100,000 children. With
the known lack of capacity for timely blood transfusion in
many areas of Africa, such numbers should lead to very
careful assessment about the possibility of severe morbid-
ity or even mortality as a result of ACT plus low-dose
primaquine MDA.
Conclusions
The addition of primaquine to ACT could be an import-
ant tool in malaria elimination campaigns. The study by
Gonçalves et al. has provided new information that high-
lights both the promise and the potential peril of adding
primaquine to ACT in children with asymptomatic para-
sitemia. The study also helps to highlight a number of
questions centered on transmission and safety that must
be answered prior to consideration of this combination
for MDA. The promise of this therapy is too great to
neglect based on theoretical concerns about toxicity, yet
the risks of implementation without a thorough assess-
ment of safety are equally great. Serious adverse events,
even in a small number of children, could set back MDA
efforts for years. So onward to the next tier of studies,
with the goal of determining a successful combination
that is both safe and effective.
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